[1]弥婉军,王晓娟.胰高血糖素样肽-1蛋白对帕金森病氧化应激损伤的保护作用及机制研究[J].陕西医学杂志,2021,50(4):395-397,402.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.003]
　MI Wanjun,WANG Xiaojuan.Protective effect and mechanism of GLP-1 protein on oxidative stress injury in Parkinson's disease[J].,2021,50(4):395-397,402.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.003]
点击复制

胰高血糖素样肽-1蛋白对帕金森病氧化应激损伤的保护作用及机制研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年4期
页码:
395-397,402
栏目:
基础研究
出版日期:
2021-04-05

文章信息/Info

Title:
Protective effect and mechanism of GLP-1 protein on oxidative stress injury in Parkinson's disease
作者:
弥婉军1; 王晓娟2
(1.渭南市中心医院神经内科,陕西 渭南 714000; 2.宝鸡市中医医院脑病二科,陕西 宝鸡 721000)
Author(s):
MI Wanjun; WANG Xiaojuan
(Department of Neurology,Weinan Central Hospital,Weinan 714000,China)
关键词:
胰高血糖素样肽-1;  帕金森病;  氧化应激;  GLP-1/GIP双受体激动剂;  神经保护;  机制
Keywords:
Glucagon-like peptide-1;  Parkinson's disease;  Oxidative stress;  GLP-1/GIP dual receptor agonist;  Neuroprotection;  Mechanism
分类号:
R 745.1
DOI:
DOI:10.3969/j.issn.1000-7377.2021.04.003
文献标志码:
A
摘要:
目的:探讨胰高血糖素样肽-1(GLP-1)蛋白对帕金森病氧化应激损伤的保护作用及机制。方法:36只8周龄C57BL/6 雄性小鼠随机平分为三组(模型组、利拉鲁肽组与GLP-1组)。所有小鼠都给予建立帕金森病模型,模型组在建模过程中给予0.1 ml 0.9%氯化钠溶液注射,利拉鲁肽组在给予利拉鲁肽腹腔注射25 nmol/(kg·d),GLP-1组在建给予GLP-1/GIP双受体激动剂(DA3-CH)腹腔注射25 nmol/(kg·d),连续治疗7 d。结果:三组建模第7天的转棒停留时间、牵拉肌张力评分都低于建模第1天(均P<0.05),利拉鲁肽组与GLP-1组高于模型组(P<0.05),GLP-1组高于利拉鲁肽组(均P<0.05)。利拉鲁肽组与GLP-1组建模第7天的血清Chi3l1含量、脑组织IBA-1和胶质纤维酸性蛋白(GFAP)相对表达水平低于模型组(均P<0.05),GLP-1组低于利拉鲁肽组(P<0.05)。结论:GLP-1蛋白在帕金森病小鼠的应用能缓解氧化应激损伤,抑制血清Chi3l1与脑组织IBA-1、GFAP蛋白的表达,从而发挥神经保护作用。
Abstract:
Objective:To explore the protective effect and mechanism of glucagon-like peptide-1(GLP-1)protein on oxidative stress injury in Parkinson's disease.Methods:36 cases of 8-week-old C57BL/6 male mice were randomly divided into model group,liraglutide group and GLP-1 group.All mice were constructed of Parkinson's disease model.The model group was injected with 0.1 ml of 0.9% sodium chloride solution during the modeling process,the liraglutide group was given intraperitoneal injection of 25 nmol/(kg·d)with liraglutide,and the GLP-1 group was given intraperitoneal injection of 25 nmol/(kg·d)of GLP-1/GIP dual receptor agonist(DA3-CH)for 7 consecutive days.Results:The rotor stay time and stretch muscle tension scores on the 7th day of the three groups of modeling were lower than those on the 1st day of modeling(all P<0.05),and the liraglutide group and GLP-1 group were higher than the model group(P<0.05),and the GLP-1 group were higher than the liraglutide group(all P<0.05).The serum Chi3l1 content and the relative expression levels of brain tissue IBA-1 and GFAP proteins of the liraglutide group and the GLP-1 group were lower than those of the model group on the 7th day of modeling(all P<0.05),and the GLP-1 group were lower than the liraglutide group(all P<0.05).Conclusion:The application of GLP-1 protein in Parkinson's disease mice can alleviate oxidative stress damage and inhibit the expression of serum Chi3l1 and brain tissue IBA-1 and GFAP proteins,thereby exerting neuroprotective effects.

参考文献/References:

[1] 吴成举,英锡相,陈 靖,等.针刺疗法对帕金森病大鼠黑质神经元凋亡蛋白bcl-2、bax的影响[J].陕西中医,2020,41(1):8-11,133.
[2] 何剑波,李会琪,翟洁敏,等.复方左旋多巴制剂与帕金森病患者同型半胱氨水平及认知损害的相关性分析[J].陕西医学杂志,2017,46(2):250-252.
[3] 刘东华,荆凡波,全香花,等.基因多态性与胰高血糖素样肽1受体激动剂疗效的相关性研究进展[J].中国药房,2020,31(2):245-250.
[4] 中华医学会内分泌学分会,中华医学会糖尿病学分会.胰高糖素样肽-1(GLP-1)受体激动剂用于治疗2型糖尿病的临床专家共识[J].中华内科杂志,2020,59(11):836-846.
[5] 章若愚,王鸿妹,赵绍光,等.GLP-1受体激动剂与2型糖尿病患者肿瘤风险[J].中国医师进修杂志,2020,43(4):382-384.
[6] 姜 露,厉 平.GLP-1类似物和受体激动剂对2型糖尿病合并肥胖及单纯肥胖患者体重影响的研究进展[J].医学综述,2020,26(2):341-345.
[7] Glotfelty EJ,Olson L,Karlsson TE,et al.Glucagon-like peptide-1(GLP-1)-based receptor agonists as a treatment for Parkinson's disease[J].AMB Express,2020,29(6):595-602.
[8] 纪立伟,郭立新.胰高糖素样肽-1类药物的心血管保护作用[J].中华糖尿病杂志,2020,12(8):654-660.
[9] 郑晓辉,宋轶萱,史桂玲,等.度拉糖肽治疗2型糖尿病的临床研究进展[J].现代药物与临床,2020,35(1):184-188.
[10] 丁立新.胰升糖素样肽1与胰升糖素样肽1受体激动剂的血压效应及作用机制的研究进展[J].中华内分泌代谢杂志,2020,36(9):811-816.
[11] 程雪梅,戚 筠.甘精胰岛素联合GLP-1受体激动剂对2型糖尿病患者胰岛素功能及血糖的影响[J].药物生物技术,2020,27(2):127-130.
[12] Kortam MA,Rabie MA,Mohamed AF,et al.Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes[J].Neurotherapeutics,2020,143(10):2868-2871.
[13] Sun J,Li H,Jin Y,et al.Probiotic clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway[J].Expert Opin Investig Drugs,2021,91(11):703-715.
[14] Zhang L,Li Y.The novel dual GLP-1/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson's disease[J].J Parkinsons Dis,2020,10(2):523-542.
[15] Li T,Tu L,Gu R,et al.Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model[J].Life Sci,2020,256(9):1178-1182.
[16] Mulvaney CA,Duarte GS,Handley J,et al.GLP-1 receptor agonists for Parkinson's disease[J].Cochrane Database Syst Rev,2020,7(7):1299.
[17] Qiu X,Huang Y,Cen L,et al.Association of GLP-1 receptor gene polymorphisms with sporadic Parkinson's disease in Chinese Han population[J].Neurosci Lett,2020,728(13):1354.
[18] 谷伟军,母义明.胰高糖素样肽-1受体激动剂在2型糖尿病治疗中的地位变迁[J].药品评价,2020,17(z1):5-8.
[19] 李 琳,李全民.胰高糖素样肽-1受体激动剂周制剂的中国证据[J].药品评价,2020,17(1):33-37.
[20] Brauer R,Wei L,Ma T,et al.Diabetes medications and risk of Parkinson's disease:A cohort study of patients with diabetes[J].Brain,2020,143(10):3067-3076.

相似文献/References:

[1]王松海,许 鹏,康 超,等.红景天苷对MPTP-帕金森病小鼠模型自噬通路影响的实验研究[J].陕西医学杂志,2020,49(10):1215.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.004]
　WANG Songhai,XU Peng,KANG Chao,et al.Effect of salidroside on the autophagy pathway in the MPTP-induced mouse model of Parkinson's disease[J].,2020,49(4):1215.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.004]
[2]王松海,康 超,谢燕华,等.红景天苷通过抑制线粒体自噬通路减轻1-甲基-4-苯基吡啶离子诱导的PC12细胞凋亡实验研究[J].陕西医学杂志,2021,50(6):652.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.003]
　WANG Songhai,KANG Chao,XIE Yanhua,et al.Experimental study of salidroside attenuating MPP+-induced apoptosis of PC12 cells through inhibiting mitochondrial autophagy pathway[J].,2021,50(4):652.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.003]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2018ZDXM-SF-052)
更新日期/Last Update: 2021-04-06